MARA Reports June 2025 Bitcoin Production and Mining Operations Update, Issues Mid-Year Outlook
211Blocks Won inJune,25%DecreaseM/M
IncreasedBTC Holdings* to49,940BTC
Miami, FL, July 01, 2025 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA ) ('MARA' or the 'Company'), a leading digital energy and infrastructure company, today published unaudited bitcoin ('bitcoin' or 'BTC') production updates for June 2025 and provided its hashrate outlook for the full year.
Management Commentary
'With 1.7 gigawatts ('GW') of captive capacity – including 1.1 GW currently operational – and a growth pipeline exceeding 3 GW of low-cost power opportunities, we are targeting 75 exahash by the end of 2025. This target represents over 40% growth from 2024, supported by machine orders already in place,' said Fred Thiel, MARA's chairman and CEO. 'As the largest public bitcoin miner, this goal aligns with both our rapid expansion and commitment to low-cost power with efficient capital deployment.
'Following a record-breaking May, production in June came in lower, with 211 blocks won for the month. The decrease was primarily due to reduced uptime from weather-related curtailment and the temporary deployment of older machines in Garden City while storm-related damage was being remediated. Natural variability in block luck – an expected dynamic when operating our own mining pool – also contributed.
'We're excited to be approaching 50,000 bitcoin, a testament to the scale of our operations and the strength of our strategy. This milestone reflects our disciplined approach to accumulating bitcoin through both mining and strategic purchases, and our continued commitment to building long-term value for our shareholders.'
Operational Highlights and Updates
Figure 1: Operational Highlights
NM - Not Meaningful
As of June 30, 2025, the Company held a total of 49,940 BTC*. MARA opted not to sell any BTC in June.
*Includes 15,534 bitcoin that is loaned, pledged as collateral or held in a separately managed account for the benefit of the Company.
Investor Notice
Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under the heading 'Risk Factors' in our most recent annual report on Form 10-K and any other periodic reports that we may file with the U.S. Securities and Exchange Commission (the 'SEC'). If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See 'Forward-Looking Statements' below.
The operational highlights and updates presented in this press release pertain solely to our bitcoin mining operations. Detailed information regarding our other operations can be found in our periodic reports filed with the SEC. The bitcoin production figures provided are estimates and may be subject to adjustment in our periodic reports filed with the SEC.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements, other than statements of historical fact, included in this press release are forward-looking statements. The words 'may,' 'will,' 'could,' 'anticipate,' 'expect,' 'intend,' 'believe,' 'continue,' 'target' and similar expressions or variations or negatives of these words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among other things, statements related to our full-year exahash outlook, our growth pipeline and our bitcoin treasury strategy. Such forward-looking statements are based on management's current expectations about future events as of the date hereof and involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Subsequent events and developments, including actual results or changes in our assumptions, may cause our views to change. We do not undertake to update our forward-looking statements except to the extent required by applicable law. Readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements. Our actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including, but not limited to, the factors set forth under the heading 'Risk Factors' in our most recent annual report on Form 10-K, and any other periodic reports that we may file with the SEC.
About MARA
MARA (NASDAQ:MARA) deploys digital energy technologies to advance the world's energy systems. Harnessing the power of compute, MARA transforms excess energy into digital capital, balancing the grid and accelerating the deployment of critical infrastructure. Building on its expertise to redefine the future of energy, MARA develops technologies that reduce the energy demands of high-performance computing applications, from AI to the edge.
For more information, visit www.mara.com, or follow us on:
Twitter: @MARA
LinkedIn: www.linkedin.com/company/maraholdings
Facebook: www.facebook.com/MARAHoldings
Instagram: @maraholdingsinc
MARA Company Contact:
Telephone: 800-804-1690
Email: [email protected]
MARA Media Contact:
Email: [email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
The Blockchain Group Raises $13M to Advance Bitcoin Treasury Vision
The Blockchain Group (ALTBG), listed on Euronext Growth Paris has secured roughly 11 million euros ($13 million) in fresh funding as it doubles down on becoming Europe's first bitcoin (BTC) treasury company. This strategic move underscores the firm's commitment to growing its bitcoin holdings relative to its share count, aiming to deliver long-term value to investors through exposure to digital assets. Part of the fundraising included $1.18 million capital increase at 5.251 euro per share, completed under an 'ATM-type' agreement with asset manager TOBAM. In parallel, the company's wholly owned Luxembourg subsidiary issued 10 million euros ($11.8 million) in convertible bonds, priced at 5.174 euro per share, reflecting a 30 percent premium over the June 27 closing price. TOBAM subscribed for 5 million euros while bitcoin pioneer Adam Back invested around 5 million euros. The Blockchain Group currently hold 1,794 BTC, while the share price is up 1% on Tuesday.
Yahoo
an hour ago
- Yahoo
Oxley Bridge Acquisition Limited Announces the Pricing of $220,000,000 Initial Public Offering
Vancouver, BC, June 24, 2025 (GLOBE NEWSWIRE) -- Oxley Bridge Acquisition Limited (the 'Company') announced today the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Global Stock Market LLC ('Nasdaq') and begin trading on June 25, 2025, under the ticker symbol 'OBAWU.' Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols 'OBA' and 'OBAWW,' respectively. The offering is expected to close on June 26, 2025, subject to customary closing conditions. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,300,000 units at the initial public offering price to cover over-allotments, if any. The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution. The Company's primary focus, however, will be to search globally for a target with operations or prospects focusing on global consumer and technology sectors with disruptive growth potential through the use of technology that can benefit from operations in Asia, excluding the People's Republic of China, Hong Kong and Macau. The Company's management team is led by Jonathan Lin, its Chief Executive Officer and Chairman of the Board of Directors (the 'Board'), and Gary Chan, its Chief Financial Officer. The Board also includes Norma Chu, Enrique Gonzalez, Gan Wee Leong, and Jack Cho. Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York, New York 10022, or by email at prospectus@ by accessing the SEC's website, A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission ('SEC') and became effective on June 24, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the expected closing of the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the 'Risk Factors' section of the Company's registration statement and prospectus for the Company's initial public offering filed with the SEC. Copies of these documents are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Investor Contacts Oxley Bridge Acquisition LimitedJonathan
Business Wire
an hour ago
- Business Wire
SAIF Partners Sends Letter to Sinovac Shareholders
NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., ('SAIF Partners'), the largest single investor in Sinovac Biotech Ltd. ('Sinovac' or the 'Company'), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board's empty promises to shareholders, numerous failures overseeing the Company, and certain directors' concerning patterns of reckless, unethical and illegal actions to retain control of Sinovac. The full text of the letter is as follows: Dear Fellow Sinovac Shareholders, SAIF Partners ('we' or 'us') is the largest single investor and a long-term shareholder in Sinovac Biotech Ltd. ('Sinovac' or the 'Company'). We beneficially own approximately 15% of the Company's outstanding common shares. As you are likely aware, on June 24, 2025, Sinovac's Board of Directors (the 'Board') announced its intention to pay 'up to' $138.73 per share in total dividends to shareholders – a significant increase from Sinovac's previously announced $55 per share dividend scheduled to be distributed on or about July 7, 2025. As a financial investor in Sinovac just like you, we welcome the idea of the Company distributing these significant dividends. However, we have serious doubts that the current Board will be able to deliver any further dividends to you. Don't Believe Empty Promises: Sinovac's Current Board Failed to Act Until it Was Pressured by Shareholders and Became Desperate to Win Your Votes to Retain Control of Sinovac Shareholders should not be fooled by the current Board's empty promises intended to protect the status quo and retain their positions. Sinovac's current directors – the majority of whom were not duly elected by shareholders – have offered up such large dividends only because their positions are on the line at the upcoming Special Meeting of Shareholders (the 'Special Meeting') to be held on July 8, 2025, and they are trying to buy shareholders' support. Further, the misleading dividend plan outlined by the current Board reveals its recklessness and its ignorance of the nature of Sinovac's business, the financial status of the Company, and the applicable PRC laws and regulations under which the Company operates: All of Sinovac's profits over the past several years were created by the former Board and management team. The current Board contributed nothing to the generation of the Company's profits. The previously-announced $55 per share dividend – for which the current Board is seeking to take credit – was distributed from Sinovac's Chinese subsidiaries to the Company before 2025 by the former Board and was made ready for further distribution to shareholders by the former Board and management, not the current Board. That dividend was originally withheld because of the chaos created by the lawsuit regarding the 2018 takeover of Sinovac's Board by representatives of minority shareholders 1Globe and Orbimed. The current Board only recently announced its plan to distribute the dividend once it faced public pressure from shareholders including SAIF Partners. This chaotic lawsuit – led by the belligerent 1Globe and Orbimed group – has mired Sinovac in a series of legal battles that have left shareholders unable to trade the Company's stock or receive long-overdue dividend payments. If the current Board is not removed, we believe shareholders' capital will remain trapped within the Company indefinitely. Further, under the current Board, Sinovac's independent auditor, Grant Thornton Zhitong Certified Public Accountants LLP ('Grant Thornton'), resigned on April 21, 2025, and since then the Company has operated without an auditor. Given that Grant Thornton's resignation was prompted by the current Board's governance failures, we have good reason to believe that no auditor will work for Sinovac until there is a fundamental change in the Company's governance practices. We do not believe the current Board will be able to retain a new auditor given its long-term conflict with management and other shareholders. Given these realities, it appears to us that Sinovac's current Board has thrown out a massive dividend figure purely to win your votes – without consulting the people who run the Company, and without audited financial data required to make an informed judgement regarding the Company's capacity to pay dividends. The 1Globe and Orbimed Group Have Taken Reckless, Unethical and Illegal Actions to Take Control of Sinovac Sinovac operates within the highly regulated public health sector. It is critical that the Company maintains the highest respect for laws and ethics, requiring that it has principled, ethical leaders at its helm. However, the 1Globe and Orbimed group have employed a reckless approach and have previously acted with flagrant disregard for both professional ethics and applicable laws. For instance: In or about November 2018, Sinovac directors Mr. Pengfei Li and Mr. Jianzeng Cao – both directors nominated by 1Globe and Orbimed – were prohibited by the Hong Kong High Court from purporting to act or holding themselves out as Directors of Sinovac Hong Kong or its subsidiaries. The Hong Kong High Court found that Mr. Li and Mr. Cao forged documents and illegally filed them with the Hong Kong Companies Registry in an attempt to unlawfully remove Directors of Sinovac Hong Kong, and to deceive the Hong Kong Companies Registry into believing that the Board of Sinovac Hong Kong had been reconstituted. In May of 2020, the U.S. Securities and Exchange Commission (the 'SEC') found that Dr. Chiang Li and 1Globe violated federal securities laws and regulations and imposed civil money penalties on them. Specifically, the SEC found that by the end of 2017, 1Globe, Dr. Chiang Li and Dr. Chiang Li's relatives 'together held nearly one-third of the common stock of [Sinovac] and participated in an activist plan to replace four of five incumbent directors . . . at Sinovac's 2018 annual shareholder meeting.' 1Globe and Dr. Chiang Li, however, 'failed to disclose their full beneficial ownership of Sinovac stock, inclusive of substantial shares held by related parties, and their participation in a plan, led by other investors, thereby depriving existing and potential shareholders of information necessary to make fully informed investment decisions.' Based on its findings, the SEC ordered that 1Globe and Dr. Chiang Li cease and desist from committing or causing any violations and any future violations of Sections 13(d)(1) and 13(d)(2) of the Exchange Act and Rules 13d–1 and 13d–2 thereunder. The SEC also imposed civil penalties on both 1Globe and Dr. Chiang Li, with 1Globe agreeing to pay USD $200,000 and Dr. Chiang Li agreeing to pay USD $90,000 in civil money penalties. In or about February 2024, it was reported that Shandong Sinobioway Biomedicine Co., Ltd. ('Shandong Sinobioway', a public listed company in the PRC), had received a criminal judgment from the People's Court of Zhangdian District, Zibo City, Shandong Province ('Shandong Court'), in which Mr. Pengfei Li was one of the named defendants. Mr. Pengfei Li is the CEO of 1Globe China, and it is believed he committed the criminal behaviors as part of 1Globe's scheme to take control of Sinovac and its subsidiaries. The Shandong Court found that Mr. Pengfei Li had committed the crimes of embezzlement, forging government documents and seals, and forging company seals, and sentenced him to eight years in prison and ordered that he pay a fine of RMB 780,000. In addition, the Shandong Court ruled that Hangzhou Qiangxin Biotechnology Co., Ltd., a Chinese subsidiary of 1Globe, had illegally acquired a 34% equity interest in Sinobioway Biomedicine Co., Ltd., a wholly owned subsidiary of Shandong Sinobioway and the minority shareholder of Sinovac's Beijing joint venture. Given these unscrupulous behaviors over a long period of time, we strongly doubt that the current Board will ever be able to build the internal and external support to effectively oversee Sinovac, maintain financial discipline, and pay the significant dividends it has promised to you in an effort to win your vote. A New Board is Immediately Needed to Restore Sinovac's Credibility and Maximize Shareholder Value We believe that immediate change is needed on Sinovac's Board to unlock the tremendous value embedded in the Company for all shareholders. To that end, we have nominated ten highly qualified director candidates for election to the Board at the upcoming Special Meeting who are committed to resolving Sinovac's legal disputes, retaining a new independent auditor, and taking the steps necessary to deliver value to all shareholders, including: Immediately paying out the long-scheduled USD $55 per share dividend to shareholders; Ending the six-year trading halt of Sinovac's common shares, which has left the stock at a price of $6.47 per share – reflecting only a fraction of the Company's current value; Paying shareholders further dividends based on the Company's audited financial accounts. If elected, SAIF's nominees – who include Sinovac's founder and current CEO – will bring extensive industry knowledge, management experience, and shareholder alignment to the Board, and work closely with management to bring disciplined corporate governance, proper capital allocation, strategic foresight and operational excellence to the Company. SAIF Partners urges all Sinovac shareholders to vote the GOLD Proxy Card 'FOR' the removal of the current Board and 'FOR' the election of our ten highly qualified director nominees to the Board at the Special Meeting of Shareholders. Now is Your Chance to Elect a Board that Will Act in the Best Interest of ALL Sinovac Shareholders VOTE THE GOLD PROXY CARD TODAY YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY OR HOW FEW SHARES YOU OWN! Please vote today by telephone or via the Internet by following the easy instructions on the GOLD proxy card. If you have any questions or require assistance in authorizing a proxy or voting your common shares, please contact: Sodali & Co 430 Park Avenue, 14th Floor New York, NY 10022 Call Toll-Free in North America: (800) 662-5200 Outside of North America Call Collect: (203) 658-9400 Email: SAIF@ Expand About SAIF Partners SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices. Additional Information and Where to Find it This communication may be deemed to be solicitation material in respect of SAIF Partners' nomination of ten director nominees to Sinovac's Board. In connection with such solicitation, SAIF Partners mailed the definitive proxy statement and proxy card to shareholders of Sinovac with respect to the Special Meeting to be held in connection with the election of directors to Sinovac's Board. The definitive proxy statement mailed by SAIF Partners is also filed as Exhibit 1 to its Schedule 13D/A filed on or about June 16, 2025. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE SINOVAC SPECIAL MEETING, INCLUDING ANY DOCUMENT INCORPORATED BY REFERENCE THEREIN, CAREFULLY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE DIRECTOR NOMINEES AND THE SPECIAL MEETING AND RELATED MATTERS. Sinovac's shareholders may obtain, free of charge, the definitive version of the proxy statement, any amendments or supplements thereto, and any other relevant documents mailed by SAIF Partners in connection with the Special Meeting at
